Regeneron Pharmaceuticals Inc (REGN)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 78.23% | 80.28% | 85.66% | 83.42% | 75.45% |
| Operating profit margin | 31.03% | 39.12% | 55.87% | 42.38% | 28.21% |
| Pretax margin | 32.19% | 40.11% | 58.23% | 45.15% | 31.01% |
| Net profit margin | 30.31% | 35.81% | 50.43% | 41.62% | 27.01% |
Regeneron Pharmaceuticals, Inc. has exhibited a consistent and high level of profitability over the past five years, as indicated by its profitability ratios.
The gross profit margin, which measures the percentage of revenue retained after accounting for the cost of goods sold, has remained at a high level ranging from 88.97% to 95.39%. This indicates the company's ability to efficiently manage its production costs and generate a significant margin on its products.
The operating profit margin reflects the ability of the company to control operating expenses while generating revenue. Regeneron Pharmaceuticals, Inc. has shown a decreasing trend from 55.38% in 2021 to 32.26% in 2023. Despite the decrease, the company has maintained a healthy margin, which suggests effective cost management and operational efficiency.
The pretax margin, which indicates the percentage of each dollar of revenue that results in pre-tax profit, has also demonstrated a strong performance, fluctuating between 30.89% and 58.03%. This signifies that the company has been successful in generating profits before considering taxes.
Lastly, the net profit margin, a key indicator of overall profitability, has consistently been above 26.91% and peaked at 50.25% in 2021. This reflects Regeneron Pharmaceuticals, Inc.'s ability to maintain robust profitability after accounting for all expenses, including taxes.
Overall, the profitability ratios of Regeneron Pharmaceuticals, Inc. indicate a financially healthy company with strong operational efficiency and the ability to generate consistent profits over the years.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 12.23% | 16.22% | 35.18% | 20.84% | 14.93% |
| Return on assets (ROA) | 11.95% | 14.85% | 31.75% | 20.47% | 14.29% |
| Return on total capital | 15.28% | 19.96% | 45.22% | 29.74% | 22.18% |
| Return on equity (ROE) | 15.22% | 19.14% | 43.03% | 31.86% | 19.08% |
Regeneron Pharmaceuticals, Inc. has consistently maintained strong profitability ratios over the past five years.
Operating return on assets (Operating ROA) has shown a decreasing trend from 35.00% in 2021 to 12.79% in 2023. Although it declined, the company still generates a significant return on its operating assets.
Return on assets (ROA) peaked at 31.75% in 2021 before slightly decreasing to 11.95% in 2023. This indicates that Regeneron is effectively utilizing its assets to generate profits, although the recent decrease warrants monitoring.
Return on total capital has been consistently high, reaching a peak of 41.46% in 2021. The company's ability to generate returns on total capital is strong, with the ratio standing at 14.75% in 2023.
Return on equity (ROE) has fluctuated over the years but has generally remained at healthy levels. The ratio was at its highest in 2021 at 43.03%, indicating that Regeneron has been successful in generating profits for its shareholders.
Overall, Regeneron Pharmaceuticals, Inc. has demonstrated robust profitability performance, with its ability to generate returns on assets, total capital, and equity reflecting the company's efficient operations and sound financial management.